Type your tag names separated by a space and hit enter

Adjuvant chemotherapy in colorectal cancer

Evidence Summaries

Level of Evidence = A

Adjuvant chemotherapy increases disease-free survival although no overall survival in patients with stage II colon cancer.

A Cochrane review 1 included 33 randomized trials and 17 meta-analyses containing data on stage II colon cancer patients undergoing adjuvant therapy versus surgery alone. The participants in the trials were patients with completely resected colon (n=7,731) or rectal (n=7,600) cancers. With regards to the effect of adjuvant therapy on stage II colon cancer, the pooled relative risk ratio for overall survival was 0.96 (95% CL 0.88 to 1.05). With regards to disease-free survival, the pooled relative risk ratio was 0.83 (95% Cl 0.75 to 0.92).

References

1. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008;(3):CD005390.  [PMID:18646127]


Copyright © 2017 Duodecim Medical Publications Limited.
Adjuvant chemotherapy in colorectal cancer is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Adjuvant chemotherapy in colorectal cancer ID - 454545 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454545/all/Adjuvant_chemotherapy_in_colorectal_cancer PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -